This is a working overview of TH9507, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-05. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
=== Re–Ru === Lynne Regan (Ph.D. 1987). British biochemist and biotechnologist at the University of Edinburgh which studies interactions between proteins and nucleic acids. Jens Reich (b. 1939). German biophysicist at the Central Institute of Molecular Biology of the Academy of Sciences in Berlin-Buch, pioneer in systems biology. Founder of the New Forum (civil rights movement). Jacques Ricard (1929–2018). French biochemist at the Institut Jacques Monod known for studies of plant enzymes and for developing the concept of enzyme memory. David Rittenberg (1906–1970). American biochemist at Columbia, a pioneer in the use of radioactive tracers to study metabolism. Member Natl. Acad. Sci. USA. Alexander Rich (1924–2015). American biophysicist at MIT, whose many contributions included elucidation of the structure of collagen (with Francis Crick). Member Natl. Acad. Sci. USA. Jane S. Richardson (b. 1941). American biophysicist at Duke University, known for the ribbon diagram, a method of representing the 3D structures of proteins. Member Natl. Acad. Sci. USA. Thorburn Brailsford Robertson (1884–1930), Australian physiologist and biochemist, known for promoting the use of insulin for diabetes in Australia. Dame Carol V. Robinson (b. 1956), British chemist and mass spectroscopist at the University of Oxford known for studies of protein folding. Robert G. Roeder (b. 1942), American biochemist, pioneer in eukaryotic transcription. Irwin Rose (1926–2015). American biochemist at the University of Pennsylvania, noted for the discovery of ubiquitin-mediated protein degradation.
The Cave of the High Place in the Small Valley (Cave 181), also called the "Highest Cave", is described extensively by Albert Grünwedel, as a particularly interesting cave of the small ravine. He explains that the cave is located high up on the right side of the ravine, which accounts for the fact that its murals have been preserved from the usual iconoclastic vandalism: the faces in particular are well preserved. Also, the murals did not use gold foils for decoration, which reduced the incentive for theft. In his plates, Grünwedel illustrates the murals of the cave, where he names the cave by its official name: Hochliegende Höhle der 2. Schlucht ("Cave of the High Place in the 2nd Valley"), which is the German name for cave 181. Grünwedel explains that the structure of the cave is extremely rare, as it is not a barrel-vaulted cave: instead, the ceiling has the shape of a tent. The flatness of the sides of the tent-like ceiling is the reason why Grünwedel was able to remove easily most of the ceiling paintings in large panels, something which is impossible with the strongly curved surface of a barrel-vaulted ceiling. The tent-like ceiling is bordered by a row of seven bejewelled princes on each side. The side wall depict rather tumultuous scenes of the sermon of the Buddha, no fewer than eight of them, with a multitude of attendants in various attitudes and clothing. The entrance wall had paintings of Tocharian donors and monks on both side. Above the entrance was the usual painting of Maitreya with surrounding Devaputras.
Sponges are worldwide in their distribution, living in a wide range of ocean habitats, from the polar regions to the tropics. Most live in quiet, clear waters, because sediment stirred up by waves or currents would block their pores, making it difficult for them to feed and breathe. The greatest numbers of sponges are usually found on firm surfaces such as rocks, but some sponges can attach themselves to soft sediment by means of a root-like base. Sponges are more abundant but less diverse in temperate waters than in tropical waters, possibly because organisms that prey on sponges are more abundant in tropical waters. Glass sponges are the most common in polar waters and in the depths of temperate and tropical seas, as their very porous construction enables them to extract food from these resource-poor waters with the minimum of effort. Demosponges and calcareous sponges are abundant and diverse in shallower non-polar waters. The different classes of sponge live in different ranges of habitat:
Announced on 8 May 2024, AlphaFold 3 was co-developed by Google DeepMind and Isomorphic Labs, both subsidiaries of Alphabet. AlphaFold 3 is not limited to proteins, as it can also predict the structures of protein complexes with DNA, RNA, post-translational modifications and selected ligands and ions. AlphaFold 3 introduces the "Pairformer," a deep learning architecture inspired by the transformer, which is considered similar to, but simpler than, the Evoformer used in AlphaFold 2. The Pairformer module's initial predictions are refined by a diffusion model. This model begins with a cloud of atoms and iteratively refines their positions, guided by the Pairformer's output, to generate a 3D representation of the molecular structure. The AlphaFold server was created to provide free access to AlphaFold 3 for non-commercial research. As of November 2025, the AlphaFold 3 research paper has been directly cited more than 9,000 times.
Sources: en.wikipedia.org
== External links == Metribolone at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Methyltrienolone - William Llewellyn's Anabolic.org Archived 2016-04-07 at the Wayback Machine
The Hermetic Brotherhood of Light was a Fraternity that descended from the Fratres Lucis in the late 18th century (in turn, derived from the German Order of the Golden and Rosy Cross), and was the seed from which Ordo Templi Orientis (O.T.O.) ('Order of the Temple of the East' or 'Order of Oriental Templars') was created. Carl Kellner and Paschal Beverly Randolph were members of the Hermetic Brotherhood of Light. In Theodor Reuss' 1917 O.T.O. Constitution, it states in Article 1, Section 1:
== Notable exposures == The discovery of aflatoxin B1 came on the heels of the widespread death of turkeys in England in the summer of 1960 to some unknown disease, at the time labeled "Disease X". Over the course of 500 outbreaks, the disease claimed over 100,000 turkeys which appeared to be healthy. The widespread death was later found to be caused by Aspergillus flavus contamination of peanut meal. Twelve patients died of acute aflatoxin poisoning in several hospitals in the Machakos district of Kenya in 1981 following the consumption of contaminated maize. All patients also suffered from hepatitis. Following outbreaks of aflatoxin contamination in maize reaching 4,400 ppb in the spring of 2004, 125 individuals in Kenya died of acute hepatic failure while some 317 cases in total were reported. To date this was the largest known outbreak of aflatoxicosis in terms of fatalities documented.
=== Lung toxicity === Some studies suggest that perchlorate has toxic effects against lungs (pulmonary toxicity) as well. Studies have been performed on rabbits where perchlorate has been injected into the trachea. The lung tissue was removed and analyzed, and it was found that perchlorate injected lung tissue showed several adverse effects when compared to the control group that had been intratracheally injected with saline. Adverse effects included inflammatory infiltrates, alveolar collapse, subpleural thickening, and lymphocyte proliferation.
She was disenfranchised for two years by the country's electoral tribunal in a 3–2 decision on a gender-based political violence counterclaim filed by Foreign Minister Gabriela Sommerfeld, following Abad Rojas' initial lawsuit against Noboa and others for alleged harassment. Analysts said Noboa was focused on institutional stability and a leadership aligned with his vision of government, which reinforced his political strategy in the wake of this election.
Sources: en.wikipedia.org
== History == Founded as the "Association of Clinical Biochemists", the association has evolved as biochemistry has changed with advances in laboratory medicine. Recognizing an increasing number of medical members, the name was changed in 2005 to "Association for Clinical Biochemistry". In 2007 the "Association of Clinical Scientists in Immunology" merged with the ACB. The membership expanded in 2010 with the merger with the "Association of Clinical Microbiologists". The broader nature of the membership contributed to its renaming as ACB in 2013. The name was abbreviated to the Association for Laboratory Medicine in 2024.
== Astronomy == In astronomy, collisional excitation gives rise to spectral lines in the spectra of astronomical objects such as planetary nebulae and H II regions. In these objects, most atoms are ionised by photons from hot stars embedded within the nebular gas, stripping away electrons. The emitted electrons, (called photoelectrons), may collide with atoms or ions within the gas, and excite them. When these excited atoms or ions revert to their ground state, they will emit a photon. The spectral lines formed by these photons are called collisionally excited lines (often abbreviated to CELs). CELs are only seen in gases at very low densities (typically less than a few thousand particles per cm³) for forbidden transitions. For allowed transitions, the gas density can be substantially higher. At higher densities, the reverse process of collisional de-excitation suppresses the lines. Even the hardest vacuum produced on Earth is still too dense for CELs to be observed. For this reason, when CELs were first observed by William Huggins in the spectrum of the Cat's Eye Nebula, he did not know what they were, and attributed them to a hypothetical new element called nebulium. However, the lines he observed were later found to be emitted by extremely rarefied oxygen. CELs are very important in the study of gaseous nebulae, because they can be used to determine the density and temperature of the gas.
ADP-dependent NAD(P)H-hydrate dehydratase (EC 4.2.1.136, (6S)-β-6-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-dinucleotide hydro-lyase (ADP-hydrolysing), (6S)-6-β-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-dinucleotide hydro-lyase (ADP-hydrolysing, NADH-forming)) is an enzyme with systematic name (6S)-6β-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-dinucleotide hydro-lyase (ADP-hydrolysing; NADH-forming). This enzyme catalyses the following chemical reaction
Dwarfism has been defined as having an adult height of 147 centimetres (4 ft 10 in) or less, or alternatively, having a height of at least two standard deviations less than the mean of an individual's population, considering age, sex, and ancestry. There is a wide range of physical characteristics. Variations in individuals are identified by diagnosing and monitoring the underlying disorders. There may not be any complications outside adapting to their size. Short stature is a common replacement of the term 'dwarfism', especially in a medical context. However, those with mild skeletal dysplasias may not be affected by dwarfism. In some cases of untreated hypochondroplasia, males grow up to 165 cm (5 feet 5 inches). Though that is short in a relative context, it does not fall into the extreme ranges of the growth charts. Disproportionate dwarfism is characterized by shortened limbs or a shortened torso. In achondroplasia one has an average-sized trunk with short limbs and a larger forehead. Facial features are often affected and individual body parts may have problems associated with them. Spinal stenosis, ear infection, and hydrocephalus are common. In case of spinal dysostosis, one has a small trunk, with average-sized limbs. Proportionate dwarfism is marked by a short torso with short limbs, thus leading to a height that is significantly below average. There may be long periods without any significant growth. Sexual development is often delayed or impaired into adulthood. This dwarfism type is caused by an endocrine disorder and not a skeletal dysplasia.
== Sensitivity to antibiotics == While L. fermentum has been found to have antibiotic resistant properties, other studies have demonstrated that strains of the species are sensitive to some common antibiotics such as gentamicin, cefazolin, penicillin, trimethoprim/sulfamethoxazole, ampicillin, carbenicillin, erythromycin, amikacin, and choloramphenicol.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。